Evidence map›Paper›PMID 42266065›Full record

ArticleJournal of medicinal chemistry2026

Revisiting 2-Substituted-4(1

Sovitj Pou, Katherine M Liebman, Rolf W Winter, Aaron Nilsen, Yuexin Li, Isaiah N Lyche, Teresa M Riscoe, Jemma Montgomery, Max J Gramelspacher, Rozalia A Dodean and 16 more

Abstract read
In one paragraph

Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Sovitj PouVA Portland Healthcare System, 3710 SW US Veterans Hospital Road, Portland, Oregon 97239, United States.
Katherine M LiebmanVA Portland Healthcare System, 3710 SW US Veterans Hospital Road, Portland, Oregon 97239, United States.
Rolf W WinterVA Portland Healthcare System, 3710 SW US Veterans Hospital Road, Portland, Oregon 97239, United States.
Aaron NilsenVA Portland Healthcare System, 3710 SW US Veterans Hospital Road, Portland, Oregon 97239, United States.ORCID 0000-0002-3827-8222
Yuexin LiVA Portland Healthcare System, 3710 SW US Veterans Hospital Road, Portland, Oregon 97239, United States.
Isaiah N LycheVA Portland Healthcare System, 3710 SW US Veterans Hospital Road, Portland, Oregon 97239, United States.
Teresa M RiscoeVA Portland Healthcare System, 3710 SW US Veterans Hospital Road, Portland, Oregon 97239, United States.
Jemma MontgomeryVA Portland Healthcare System, 3710 SW US Veterans Hospital Road, Portland, Oregon 97239, United States.
Max J GramelspacherVA Portland Healthcare System, 3710 SW US Veterans Hospital Road, Portland, Oregon 97239, United States.
Rozalia A DodeanVA Portland Healthcare System, 3710 SW US Veterans Hospital Road, Portland, Oregon 97239, United States.ORCID 0000-0001-5002-4607
Lev N ZakharovCenter for Advanced Materials Characterization in Oregon (CAMCOR), Eugene, Oregon 97403, United States.
Binod NepalDepartment of Microbiology and Immunology, Drexel University College of Medicine, 2900 Queen Lane, Philadelphia, Pennsylvania 19129, United States.ORCID 0009-0000-6193-1210
Jane X KellyVA Portland Healthcare System, 3710 SW US Veterans Hospital Road, Portland, Oregon 97239, United States.ORCID 0000-0001-8871-0207
Martin J SmilksteinVA Portland Healthcare System, 3710 SW US Veterans Hospital Road, Portland, Oregon 97239, United States.
Sandhya KortagereDepartment of Microbiology and Immunology, Drexel University College of Medicine, 2900 Queen Lane, Philadelphia, Pennsylvania 19129, United States.
Akhil B VaidyaDepartment of Microbiology and Immunology, Drexel University College of Medicine, 2900 Queen Lane, Philadelphia, Pennsylvania 19129, United States.ORCID 0000-0003-1063-5571
P Holland AldayVA Portland Healthcare System, 3710 SW US Veterans Hospital Road, Portland, Oregon 97239, United States.ORCID 0000-0002-0142-2438
J Stone DoggettVA Portland Healthcare System, 3710 SW US Veterans Hospital Road, Portland, Oregon 97239, United States.ORCID 0000-0002-6098-1520
Karl KudybaExperimental Therapeutics Branch, CIDR, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States.
Norma RoncalExperimental Therapeutics Branch, CIDR, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States.
Kutub AshrafExperimental Therapeutics Branch, CIDR, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States.
Susan LeedExperimental Therapeutics Branch, CIDR, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States.
Patricia J LeeExperimental Therapeutics Branch, CIDR, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States.
Michael S MadejczykExperimental Therapeutics Branch, CIDR, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States.
Alison RothExperimental Therapeutics Branch, CIDR, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States.
Michael K RiscoeVA Portland Healthcare System, 3710 SW US Veterans Hospital Road, Portland, Oregon 97239, United States.ORCID 0000-0002-1343-5279

Funding

ORGANELLE GENOMES OF MALARIAL PARASITESR01AI028398 · NIAID · MCP HAHNEMANN UNIVERSITY · PI AKHIL B VAIDYA · 1989 to 2026
$10.1M
Optimizing ELQs for Treatment and Prevention of MalariaR01AI100569 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI Michael Kevin RISCOE · 2014 to 2026
$8.0M
Optimizing ELQs for Treatment and Prevention of MalariaR56AI100569 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI RISCOE, MICHAEL KEVIN · 2012 to 2012
$574k
NIAID NIH HHS R01 AI028398NIAID NIH HHS R01 AI100569NIAID NIH HHS R56 AI100569
6 · The paper itself

Abstract

Quinolones substituted at the 2- and 3-positions with biaryl and diphenylether groups have been investigated for their antimalarial potential. ELQ-300, with a 3-position diphenyl ether, is at an advanced stage of preclinical development. Here, we synthesize the 2-position isomer of ELQ-300, i.e., HLQ-102, and describe synthetic procedures for preparing it that avoid the use of expensive catalysts and afford access to substituted quinolones bearing substituents in the 2-position as well as the benzenoid ring and with the critical 3-position CH

Indexed as

AntimalarialsElectron Transport Complex IIIPlasmodium falciparumQuinolonesAnimalsHumansStructure-Activity RelationshipAntimalarialsElectron Transport Complex IIIQuinolones

Identifiers

PMID42266065
PMCPMC13312456

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.